TaiGen Biotech out-licenses Taigexyn in Latin America

Taiwan drug developer TaiGen Biotechnology has signed an exclusive licensing agreement with Productos Científicos SA de CV (PC), a leading Mexican pharmaceutical company, to develop and commercialize its novel antibiotic Taigexyn (nemonoxacin) in Latin America.

Under the terms of the agreement, PC will be responsible for the development, registration and commercialization of Taigexyn in the territory and assume all associated costs. The territory includes Mexico, Brazil, Colombia, Peru, Uruguay, Paraguay, Bolivia, Venezuela, Argentina, Chile, Costa Rica, Honduras, Nicaragua, Panama, Guatemala, El Salvador and Ecuador.

In exchange for the exclusive rights, TaiGen will receive an upfront payment and is eligible for additional regulatory and commercial milestones in the future. PC will purchase Taigexyn at a pre-negotiated price from TaiGen for its commercialization in the territory.